Susan M Domchek

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5226647/publications.pdf

Version: 2024-02-01

		5268	4645
335	33,229	83	170
papers	citations	h-index	g-index

346	346	346	29609
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Breast and Prostate Cancer Risks for MaleBRCA1andBRCA2Pathogenic Variant Carriers Using Polygenic Risk Scores. Journal of the National Cancer Institute, 2022, 114, 109-122.	6.3	19
2	Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer. European Urology, 2022, 81, 559-567.	1.9	17
3	Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants. Genetics in Medicine, 2022, 24, 119-129.	2.4	10
4	Targeted BRCA1/2 population screening among Ashkenazi Jewish individuals using a web-enabled medical model: An observational cohort study. Genetics in Medicine, 2022, 24, 564-575.	2.4	8
5	Abstract OT2-18-01: Harnessing olaparib, palbociclib, and endocrine therapy (HOPE): Phase I/II trial of olaparib, palbociclib and fulvestrant in patients with BRCA1/2-associated, hormone receptor-positive, HER2-negative metastatic breast cancer. Cancer Research, 2022, 82, OT2-18-01-OT2-18-01.	0.9	1
6	Abstract P2-09-01: Population-based risk estimates of clinical subtypes of breast cancer among carriers of germline pathogenic variants in cancer predisposition genes. Cancer Research, 2022, 82, P2-09-01-P2-09-01.	0.9	0
7	Abstract P2-11-21: Integration of an ancestrally unbiased polygenic risk score with the Tyrer-Cuzick breast cancer risk model. Cancer Research, 2022, 82, P2-11-21-P2-11-21.	0.9	0
8	BRCA1/2 Mutations and Cardiovascular Function in Breast Cancer Survivors. Frontiers in Cardiovascular Medicine, 2022, 9, 833171.	2.4	2
9	PTEN Loss and BRCA1 Promoter Hypermethylation Negatively Predict for Immunogenicity in BRCA-Deficient Ovarian Cancer. JCO Precision Oncology, 2022, 6, e2100159.	3.0	4
10	Polygenic risk scores for prediction of breast cancer risk in women of African ancestry: a cross-ancestry approach. Human Molecular Genetics, 2022, 31, 3133-3143.	2.9	11
11	Classification of BRCA2 Variants of Uncertain Significance (VUS) Using an ACMG/AMP Model Incorporating a Homology-Directed Repair (HDR) Functional Assay. Clinical Cancer Research, 2022, 28, 3742-3751.	7.0	7
12	A breast cancer (BC) risk model incorporating Tyrer-Cuzick version 8 (TCv8) and a polygenic risk score (PRS) for diverse ancestries.. Journal of Clinical Oncology, 2022, 40, 557-557.	1.6	1
13	Trends in and determinants of germline BRCA1/2 testing in patients with breast and ovarian cancer.. Journal of Clinical Oncology, 2022, 40, 10583-10583.	1.6	0
14	A randomized phase Ib/II study of niraparib (nira) plus nivolumab (nivo) or ipilimumab (ipi) in patients (pts) with platinum-sensitive advanced pancreatic cancer (aPDAC).. Journal of Clinical Oncology, 2022, 40, 4021-4021.	1.6	3
15	A phase 1b/2 study of the BET inhibitor ZEN-3694 in combination with talazoparib for treatment of patients with TNBC without gBRCA1/2 mutations.. Journal of Clinical Oncology, 2022, 40, 1023-1023.	1.6	5
16	A descriptive study on the treatment and outcomes of patients with platinum-sensitive, advanced, BRCA- or PALB2-related pancreatic cancer who have progressed on rucaparib.. Journal of Clinical Oncology, 2022, 40, 4131-4131.	1.6	2
17	Cancer vaccines. Cancer Cell, 2022, 40, 559-564.	16.8	15
18	The increasing importance of pathology in modern clinical trial conduct: OlympiA as a case in point. Pathology, 2022, , .	0.6	0

#	Article	IF	Citations
19	Landscape of homologous recombination reversion mutations in pancreaticobiliary malignancies.. Journal of Clinical Oncology, 2022, 40, 4156-4156.	1.6	1
20	Landscape of homologous recombination reversion mutations in gynecologic malignancies.. Journal of Clinical Oncology, 2022, 40, 5576-5576.	1.6	1
21	Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial. Lancet Oncology, The, 2022, 23, 1009-1020.	10.7	44
22	Real-world integration of genomic data into the electronic health record: the PennChart Genomics Initiative. Genetics in Medicine, 2021, 23, 603-605.	2.4	29
23	Clinical Characteristics of Patients With Pancreatic Cancer and Pathogenic ATM Alterations. JNCI Cancer Spectrum, 2021, 5, pkaa121.	2.9	10
24	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nature Communications, 2021, 12, 1078.	12.8	19
25	A Population-Based Study of Genes Previously Implicated in Breast Cancer. New England Journal of Medicine, 2021, 384, 440-451.	27.0	414
26	A prospective controlled study of sexual function and sexually related personal distress up to 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy. Menopause, 2021, 28, 748-755.	2.0	6
27	What happens after menopause? (WHAM): A prospective controlled study of depression and anxiety up to 12Âmonths after premenopausal risk-reducing bilateral salpingo-oophorectomy. Gynecologic Oncology, 2021, 161, 527-534.	1.4	9
28	Challenges and Opportunities in Engaging Primary Care Providers in BRCA Testing: Results from the BFOR Study. Journal of General Internal Medicine, 2021, , 1.	2.6	2
29	Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. New England Journal of Medicine, 2021, 384, 2394-2405.	27.0	764
30	Comprehensive Breast Cancer Risk Assessment for CHEK2 and ATM Pathogenic Variant Carriers Incorporating a Polygenic Risk Score and the Tyrer-Cuzick Model. JCO Precision Oncology, 2021, 5, 1073-1081.	3.0	9
31	The predictive ability of the 313 variantâ€“based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. Genetics in Medicine, 2021, 23, 1726-1737.	2.4	16
32	Randomized study of remote telehealth genetic services versus usual care in oncology practices without genetic counselors. Cancer Medicine, 2021, 10, 4532-4541.	2.8	14
33	What happens after menopause? (WHAM): A prospective controlled study of vasomotor symptoms and menopause-related quality of life 12â€¯months after premenopausal risk-reducing salpingo-oophorectomy. Gynecologic Oncology, 2021, 163, 148-154.	1.4	10
34	Risk of Late-Onset Breast Cancer in Genetically Predisposed Women. Journal of Clinical Oncology, 2021, 39, 3430-3440.	1.6	21
35	What Happens After Menopause? (WHAM): A prospective controlled study of cardiovascular and metabolic risk 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy. Gynecologic Oncology, 2021, 162, 88-96.	1.4	6
36	Comparison of the Prevalence of Pathogenic Variants in Cancer Susceptibility Genes in Black Women and Non-Hispanic White Women With Breast Cancer in the United States. JAMA Oncology, 2021, 7, 1045.	7.1	21

#	Article	IF	Citations
37	Uptake and acceptability of a mainstreaming model of hereditary cancer multigene panel testing among patients with ovarian, pancreatic, and prostate cancer. Genetics in Medicine, 2021, 23, 2105-2113.	2.4	29
38	Relationship of established risk factors with breast cancer subtypes. Cancer Medicine, 2021, 10, 6456-6467.	2.8	45
39	EUS-based Pancreatic Cancer Surveillance in BRCA1/BRCA2/PALB2/ATM Carriers Without a Family History of Pancreatic Cancer. Cancer Prevention Research, 2021, 14, 1033-1040.	1.5	5
40	Risk of Breast Cancer Among Carriers of Pathogenic Variants in Breast Cancer Predisposition Genes Varies by Polygenic Risk Score. Journal of Clinical Oncology, 2021, 39, 2564-2573.	1.6	47
41	Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, BRCA2, or PALB2. Journal of Clinical Oncology, 2021, 39, 2497-2505.	1.6	113
42	Innovation in germline and somatic tumor testing pathways for ovarian cancer patients. Gynecologic Oncology, 2021, 162, S30-S31.	1.4	0
43	Risk factors for breast cancer subtypes among Black women undergoing screening mammography. Breast Cancer Research and Treatment, 2021, 189, 827-835.	2.5	12
44	What happens after menopause? (WHAM): A prospective controlled study of sleep quality up to 12â€¯months after premenopausal risk-reducing salpingo-oophorectomy. Gynecologic Oncology, 2021, 162, 447-453.	1.4	9
45	Integrating Clinical and Polygenic Factors to Predict Breast Cancer Risk in Women Undergoing Genetic Testing. JCO Precision Oncology, 2021, 5, 307-316.	3.0	18
46	Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 77-102.	4.9	498
47	Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer. Gynecologic Oncology, 2021, 163, 246-253.	1.4	62
48	Germline Pathogenic Variants in Cancer Predisposition Genes Among Women With Invasive Lobular Carcinoma of the Breast. Journal of Clinical Oncology, 2021, 39, 3918-3926.	1.6	22
49	Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. Cancer Research, 2020, 80, 624-638.	0.9	39
50	Comprehensive Assessment ofÂChangesÂin Left Ventricular DiastolicÂFunction With ContemporaryÂBreast Cancer Therapy. JACC: Cardiovascular Imaging, 2020, 13, 198-210.	5.3	79
51	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nature Genetics, 2020, 52, 56-73.	21.4	120
52	Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families. Journal of Clinical Oncology, 2020, 38, 674-685.	1.6	270
53	CDH1 on Multigene Panel Testing: Look Before You Leap. Journal of the National Cancer Institute, 2020, 112, 330-334.	6.3	34
54	Germline genetic testing for breast cancer: which patients? What genes?. Genetics in Medicine, 2020, 22, 698-700.	2.4	3

#	Article	IF	Citations
55	Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation. British Journal of Cancer, 2020, 122, 333-339.	6.4	141
56	Reply to Patel and McLeod. Journal of Clinical Oncology, 2020, 38, 284-284.	1.6	0
57	Endoscopic Ultrasound Has Limited Utility in Diagnosis of Gastric Cancer in Carriers of CDH1 Mutations. Clinical Gastroenterology and Hepatology, 2020, 18, 505-508.e1.	4.4	16
58	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genetics in Medicine, 2020, 22, 1653-1666.	2.4	82
59	A Rare TP53 Mutation Predominant in Ashkenazi Jews Confers Risk of Multiple Cancers. Cancer Research, 2020, 80, 3732-3744.	0.9	32
60	Executive function after risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: does current mood and early life adversity matter?. Menopause, 2020, 27, 746-755.	2.0	13
61	The contemporary landscape of genetic testing and breast cancer: Emerging issues. Breast Journal, 2020, 26, 1549-1555.	1.0	6
62	Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. Lancet Oncology, The, 2020, 21, 1155-1164.	10.7	274
63	Association of a Polygenic Risk Score With Breast Cancer Among Women Carriers of High- and Moderate-Risk Breast Cancer Genes. JAMA Network Open, 2020, 3, e208501.	5.9	79
64	TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. Journal of Clinical Oncology, 2020, 38, 4274-4282.	1.6	276
65	Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer. Npj Breast Cancer, 2020, 6, 44.	5.2	5
66	Mutation Rates in Cancer Susceptibility Genes in Patients With Breast Cancer With Multiple Primary Cancers. JCO Precision Oncology, 2020, 4, 916-925.	3.0	9
67	Upper Gastrointestinal Cancer Risk and Surveillance Outcomes in Li-Fraumeni Syndrome. American Journal of Gastroenterology, 2020, 115, 2095-2097.	0.4	9
68	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nature Genetics, 2020, 52, 572-581.	21.4	265
69	Contribution of Germline Predisposition Gene Mutations to Breast Cancer Risk in African American Women. Journal of the National Cancer Institute, 2020, 112, 1213-1221.	6.3	51
70	Longitudinal follow-up after telephone disclosure in the randomized COGENT study. Genetics in Medicine, 2020, 22, 1401-1406.	2.4	4
71	Integrating Genetic and Genomic Testing Into Oncology Practice. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e259-e263.	3.8	6
72	Development and Validation of a Clinical Polygenic Risk Score to Predict Breast Cancer Risk. JCO Precision Oncology, 2020, 4, 585-592.	3.0	41

#	Article	IF	Citations
73	Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast Cancer. Journal of Clinical Oncology, 2020, 38, 1409-1418.	1.6	64
74	Characterization of the Cancer Spectrum in Men With GermlineBRCA1andBRCA2Pathogenic Variants. JAMA Oncology, 2020, 6, 1218.	7.1	48
75	Longitudinal outcomes with cancer multigene panel testing in previously tested BRCA1/2 negative patients. Clinical Genetics, 2020, 97, 601-609.	2.0	7
76	Loss-of-function variants in CTNNA1 detected on multigene panel testing in individuals with gastric or breast cancer. Genetics in Medicine, 2020, 22, 840-846.	2.4	30
77	Splicing profile by capture RNA-seq identifies pathogenic germline variants in tumor suppressor genes. Npj Precision Oncology, 2020, 4, 4.	5.4	47
78	Transcriptomeâ€wide association study of breast cancer risk by estrogenâ€receptor status. Genetic Epidemiology, 2020, 44, 442-468.	1.3	32
79	Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations With Cardiac Dysfunction. Journal of the American Heart Association, 2020, 9, e014708.	3.7	94
80	Frequency of radiation-induced malignancies post-adjuvant radiotherapy for breast cancer in patients with Li-Fraumeni syndrome. Breast Cancer Research and Treatment, 2020, 181, 181-188.	2.5	36
81	Association of premenopausal risk-reducing salpingo-oophorectomy with breast cancer risk in BRCA1/2 mutation carriers: Maximising bias-reduction. European Journal of Cancer, 2020, 132, 53-60.	2.8	16
82	NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 380-391.	4.9	314
83	Comprehensive breast cancer (BC) risk assessment for CHEK2 carriers incorporating a polygenic risk score (PRS) and the Tyrer-Cuzick (TC) model.. Journal of Clinical Oncology, 2020, 38, 1504-1504.	1.6	0
84	Current Insights: Evolving Principles and Controversies of Cancer Risk Assessment and Management of Hereditary Cancers. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 964-967.	4.9	0
85	Broadening Criteria for BRCA1/2 Evaluation. JAMA - Journal of the American Medical Association, 2019, 322, 619.	7.4	9
86	Research participantsâ€™ experiences with return of genetic research results and preferences for webâ€based alternatives. Molecular Genetics & Genomic Medicine, 2019, 7, e898.	1.2	24
87	The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. Npj Breast Cancer, 2019, 5, 38.	5.2	28
88	Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. European Urology, 2019, 76, 831-842.	1.9	148
89	Broad Application of Multigene Panel Testing for Breast Cancer Susceptibilityâ€"Pandoraâ€™s Box Is Opening Wider. JAMA Oncology, 2019, 5, 1687.	7.1	13
90	RE: BRCA1 and BRCA2 Gene Mutations and Colorectal Cancer Risk: Systematic Review and Meta-analysis. Journal of the National Cancer Institute, 2019, 111, 522-523.	6.3	7

#	Article	IF	Citations
91	Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification. Human Mutation, 2019, 40, 1557-1578.	2.5	102
92	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. British Journal of Cancer, 2019, 121, 180-192.	6.4	19
93	How Should Patients and Providers Interpret the US Food and Drug Administrationâ€™s Regulatory Language for Direct-to-Consumer Genetic Tests?. Journal of Clinical Oncology, 2019, 37, 2514-2517.	1.6	10
94	BRCA1andBRCA2pathogenic sequence variants in women of African origin or ancestry. Human Mutation, 2019, 40, 1781-1796.	2.5	26
95	Towards controlled terminology for reporting germline cancer susceptibility variants: an ENIGMA report. Journal of Medical Genetics, 2019, 56, 347-357.	3.2	32
96	Detailed phenotyping reveals distinct trajectories of cardiovascular function and symptoms with exposure to modern breast cancer therapy. Cancer, 2019, 125, 2762-2771.	4.1	10
97	Genomic Signatures Predict the Immunogenicity of BRCA-Deficient Breast Cancer. Clinical Cancer Research, 2019, 25, 4363-4374.	7.0	60
98	Risk factors for sexual dysfunction in BRCA mutation carriers after risk-reducing salpingo-oophorectomy. Menopause, 2019, 26, 132-139.	2.0	20
99	Identification and Confirmation of Potentially Actionable Germline Mutations in Tumor-Only Genomic Sequencing. JCO Precision Oncology, 2019, 3, 1-11.	3.0	20
100	Preferences for inâ€person disclosure: Patients declining telephone disclosure characteristics and outcomes in the multicenter Communication Of GENetic Test Results by Telephone study. Clinical Genetics, 2019, 95, 293-301.	2.0	16
101	Earlier Colorectal Cancer Screening May Be Necessary In Patients With Li-Fraumeni Syndrome. Gastroenterology, 2019, 156, 273-274.	1.3	19
102	Combination Paclitaxel and Palbociclib: Results of a Phase I Trial in Advanced Breast Cancer. Clinical Cancer Research, 2019, 25, 2072-2079.	7.0	29
103	Cardiovascular Function Phenotypes in Response to Cardiotoxic Breast Cancer Therapy. Journal of the American College of Cardiology, 2019, 73, 248-249.	2.8	10
104	Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. Journal of the National Cancer Institute, 2019, 111, 350-364.	6.3	30
105	Risk-Reducing Mastectomy in BRCA1 and BRCA2 Mutation Carriers. JAMA - Journal of the American Medical Association, 2019, 321, 27.	7.4	26
106	Preventative Health and Risk Behaviors Among Adolescent Girls With and Without Family Histories of Breast Cancer. Journal of Adolescent Health, 2019, 64, 116-123.	2.5	3
107	Ten-fold increase in genetic testing in pancreatic and metastatic prostate cancer with implementation of point of care (POC) testing.. Journal of Clinical Oncology, 2019, 37, 1506-1506.	1.6	7
108	A randomized phase II trial of niraparib plus either nivolumab or ipilimumab in patients with advanced pancreatic cancer whose cancer has not progressed on platinum-based therapy.. Journal of Clinical Oncology, 2019, 37, TPS4161-TPS4161.	1.6	11

#	Article	IF	Citations
109	An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in patients with relapsed gastric cancer.. Journal of Clinical Oncology, 2019, 37, 140-140.	1.6	37
110	EMR documentation of genetics evaluations in patients with ovarian cancer.. Journal of Clinical Oncology, 2019, 37, e13156-e13156.	1.6	0
111	Genetic predisposition to breast cancer among African American women.. Journal of Clinical Oncology, 2019, 37, 104-104.	1.6	0
112	Randomized Noninferiority Trial of Telephone vs In-Person Disclosure of Germline Cancer Genetic Test Results. Journal of the National Cancer Institute, 2018, 110, 985-993.	6.3	35
113	A counseling framework for moderate-penetrance colorectal cancer susceptibility genes. Genetics in Medicine, 2018, 20, 1324-1327.	2.4	31
114	Mutational spectrum in a worldwide study of 29,700 families withBRCA1orBRCA2mutations. Human Mutation, 2018, 39, 593-620.	2.5	224
115	Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. British Journal of Cancer, 2018, 118, 266-276.	6.4	12
116	Retrospective Survival Analysis of Patients With Advanced Pancreatic Ductal Adenocarcinoma and Germline BRCA or PALB2 Mutations. JCO Precision Oncology, 2018, 2, 1-9.	3.0	30
117	Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy. Journal of Clinical Oncology, 2018, 36, 3134-3143.	1.6	43
118	Rapid detection of BRCA1/2 recurrent mutations in Chinese breast and ovarian cancer patients with multiplex SNaPshot genotyping panels. Oncotarget, 2018, 9, 7832-7843.	1.8	9
119	Returning Individual Genetic Research Results to Research Participants: Uptake and Outcomes Among Patients With Breast Cancer. JCO Precision Oncology, 2018, 2, 1-24.	3.0	15
120	BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2. PLoS Genetics, 2018, 14, e1007752.	3.5	148
121	T143. Contribution of Mood Symptoms to Early Life Adversity Effects on Executive Function After Risk Reduction Salpingo-Oophorectomy. Biological Psychiatry, 2018, 83, S183-S184.	1.3	0
122	Pervasive genetic testing. Lancet, The, 2018, 391, 2089-2091.	13.7	3
123	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Research, 2018, 78, 5419-5430.	0.9	54
124	Ethical Implications of Direct-to-Consumer Hereditary Cancer Tests. JAMA Oncology, 2018, 4, 1327.	7.1	13
125	Uptake of BRCA 1/2 and oncotype DX testing by medical and surgical oncologists. Breast Cancer Research and Treatment, 2018, 171, 173-180.	2.5	4
126	A single arm phase II study of rucaparib maintenance in patients with advanced pancreatic adenocarcinoma and a known deleterious BRCA1, BRCA2 or PALB2 mutation who have achieved stability on platinum therapy.. Journal of Clinical Oncology, 2018, 36, TPS531-TPS531.	1.6	3

#	Article	IF	Citations
127	The evolution of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer. Clinical Advances in Hematology and Oncology, 2018, 16, 330-332.	0.3	1
128	Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk â€“ Combined Results from Two Screening Trials. Clinical Cancer Research, 2017, 23, 3628-3637.	7.0	99
129	Immunotherapy for Breast Cancer: What Are We Missing?. Clinical Cancer Research, 2017, 23, 2640-2646.	7.0	176
130	Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. New England Journal of Medicine, 2017, 377, 523-533.	27.0	2,256
131	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	21.4	356
132	A Phase Iâ€“II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors. Clinical Cancer Research, 2017, 23, 4095-4106.	7.0	213
133	Olaparib for Metastatic Germline BRCA-Mutated Breast Cancer. New England Journal of Medicine, 2017, 377, 1792-1793.	27.0	55
134	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	21.4	289
135	Reversion Mutations with Clinical Use of PARP Inhibitors: Many Genes, Many Versions. Cancer Discovery, 2017, 7, 937-939.	9.4	33
136	BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers. Nature Communications, 2017, 8, 319.	12.8	212
137	Arginine-Nitric Oxide Metabolites and Cardiac Dysfunction in Patients With Breast Cancer. Journal of the American College of Cardiology, 2017, 70, 152-162.	2.8	87
138	A functionally significant SNP in TP53 and breast cancer risk in African-American women. Npj Breast Cancer, 2017, 3, 5.	5.2	44
139	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Research and Treatment, 2017, 161, 117-134.	2.5	18
140	Reproductive Decisionâ€Making in Women with BRCA1/2 Mutations. Journal of Genetic Counseling, 2017, 26, 594-603.	1.6	61
141	A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. Future Oncology, 2017, 13, 307-320.	2.4	41
142	Physical and psychological health in rare cancer survivors. Journal of Cancer Survivorship, 2017, 11, 158-165.	2.9	16
143	Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. Journal of the National Cancer Institute, 2017, 109, .	6.3	242
144	Reply to R.L. Nussbaum et al and J.S. Dolinsky et al. Journal of Clinical Oncology, 2017, 35, 1262-1263.	1.6	1

#	Article	IF	Citations
145	Identifying Health Information Technology Needs of Oncologists to Facilitate the Adoption of Genomic Medicine: Recommendations From the 2016 American Society of Clinical Oncology Omics and Precision Oncology Workshop. Journal of Clinical Oncology, 2017, 35, 3153-3159.	1.6	20
146	Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. Journal of Clinical Oncology, 2017, 35, 2240-2250.	1.6	152
147	Extended follow-up in the COGENT study: A randomized study of in-person versus telephone disclosure of cancer genetic test results.. Journal of Clinical Oncology, 2017, 35, 1504-1504.	1.6	0
148	Knowledge outcomes in a randomized trial of telephone vs. in-person disclosure of genetic testing: The COGENT study.. Journal of Clinical Oncology, 2017, 35, 1534-1534.	1.6	0
149	Refining Breast Cancer Risk Stratification: Additional Genes, Additional Information. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, 44-56.	3.8	19
150	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS ONE, 2016, 11, e0158801.	2.5	10
151	Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations. JAMA Oncology, 2016, 2, 1434.	7.1	189
152	Response: Table 1.. Journal of the National Cancer Institute, 2016, 108, djw173.	6.3	2
153	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Research, 2016, 18, 64.	5.0	31
154	Noninvasive Measures of Ventricular-Arterial Coupling and Circumferential Strain Predict Cancer Therapeuticsâ€“Related Cardiac Dysfunction. JACC: Cardiovascular Imaging, 2016, 9, 1131-1141.	5.3	85
155	Evaluation of ACMG-Guideline-Based Variant Classification of Cancer Susceptibility and Non-Cancer-Associated Genes in Families Affected by Breast Cancer. American Journal of Human Genetics, 2016, 98, 801-817.	6.2	113
156	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research, 2016, 18, 15.	5.0	88
157	Adjuvant ovarian function suppression and cognitive function in women with breast cancer. British Journal of Cancer, 2016, 114, 956-964.	6.4	38
158	An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2016, 157, 319-327.	2.5	26
159	Health Care Segregation, Physician Recommendation, and Racial Disparities inBRCA1/2Testing Among Women With Breast Cancer. Journal of Clinical Oncology, 2016, 34, 2610-2618.	1.6	136
160	Baseline Immunoglobulin E Levels as a Marker of Doxorubicin- and Trastuzumab-Associated Cardiac Dysfunction. Circulation Research, 2016, 119, 1135-1144.	4.5	40
161	Population Frequency of Germline BRCA1/2 Mutations. Journal of Clinical Oncology, 2016, 34, 4183-4185.	1.6	107
162	Genome-wide association studies in women of African ancestry identified 3q26.21 as a novel susceptibility locus for oestrogen receptor negative breast cancer. Human Molecular Genetics, 2016, 25, ddw305.	2.9	50

#	Article	IF	Citations
163	Conflicting Interpretation of Genetic Variants and Cancer Risk by Commercial Laboratories as Assessed by the Prospective Registry of Multiplex Testing. Journal of Clinical Oncology, 2016, 34, 4071-4078.	1.6	147
164	A Recurrent ERCC3 Truncating Mutation Confers Moderate Risk for Breast Cancer. Cancer Discovery, 2016, 6, 1267-1275.	9.4	41
165	Psychosocial Adjustment and Perceived Risk Among Adolescent Girls From Families With BRCA1/2 or Breast Cancer History. Journal of Clinical Oncology, 2016, 34, 3409-3416.	1.6	16
166	Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. Breast Cancer Research, 2016, 18, 112.	5.0	42
167	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nature Communications, 2016, 7, 11375.	12.8	93
168	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breastâ€“ovarian cancer susceptibility locus. Nature Communications, 2016, 7, 12675.	12.8	78
169	Use of systemic hormone therapy in BRCA mutation carriers. Menopause, 2016, 23, 1026-1027.	2.0	24
170	Counselling framework for moderate-penetrance cancer-susceptibility mutations. Nature Reviews Clinical Oncology, 2016, 13, 581-588.	27.6	258
171	Exercise-Induced Dose-Response Alterations in Adiponectin and Leptin Levels Are Dependent on Body Fat Changes in Women at Risk for Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1195-1200.	2.5	33
172	Patient feedback and early outcome data with a novel tiered-binned model for multiplex breast cancer susceptibility testing. Genetics in Medicine, 2016, 18, 25-33.	2.4	56
173	Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. Gynecologic Oncology, 2016, 140, 199-203.	1.4	252
174	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nature Genetics, 2016, 48, 374-386.	21.4	125
175	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology, 2016, 141, 386-401.	1.4	18
176	Patterns and predictors of BRCA 1/2 testing in young breast cancer survivors.. Journal of Clinical Oncology, 2016, 34, 1514-1514.	1.6	1
177	Prospective registry of multiplex testing (PROMPT): A web-based platform to assess cancer risk of genetic variants.. Journal of Clinical Oncology, 2016, 34, 1518-1518.	1.6	3
178	Refining Breast Cancer Risk Stratification: Additional Genes, Additional Information. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 36, 44-56.	3.8	12
179	Utilizing Remote Real-Time Videoconferencing to Expand Access to Cancer Genetic Services in Community Practices: A Multicenter Feasibility Study. Journal of Medical Internet Research, 2016, 18, e23.	4.3	79
180	Cancer susceptibility mutations in individuals with breast and ovarian cancer using next-generation sequencing.. Journal of Clinical Oncology, 2016, 34, 1515-1515.	1.6	2

#	Article	IF	Citations
181	Patient-reported outcomes in a multicenter randomized study of in-person versus telephone disclosure of genetic test results for cancer susceptibility.. Journal of Clinical Oncology, 2016, 34, 1502-1502.	1.6	0
182	Identification of genetic test results with conflicting interpretations in prospective registry of multiplex testing (PROMPT).. Journal of Clinical Oncology, 2016, 34, 1510-1510.	1.6	38
183	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Research, 2015, 17, 61.	5.0	26
184	Quantitative assessment of background parenchymal enhancement in breast MRI predicts response to risk-reducing salpingo-oophorectomy: preliminary evaluation in a cohort of BRCA1/2 mutation carriers. Breast Cancer Research, 2015, 17, 67.	5.0	49
185	Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers. PLoS ONE, 2015, 10, e0120020.	2.5	34
186	Gene-Panel Sequencing and the Prediction of Breast-Cancer Risk. New England Journal of Medicine, 2015, 372, 2243-2257.	27.0	764
187	DCIS in BRCA1 and BRCA2 mutation carriers: prevalence, phenotype, and expression of oncodrivers C-MET and HER3. Journal of Translational Medicine, 2015, 13, 335.	4.4	16
188	CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment. Clinical Cancer Research, 2015, 21, 995-1001.	7.0	293
189	Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation. Journal of Clinical Oncology, 2015, 33, 244-250.	1.6	1,473
190	Women In Steady Exercise Research (WISER) Sister: Study design and methods. Contemporary Clinical Trials, 2015, 41, 17-30.	1.8	19
191	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	21.4	221
192	Association of Type and Location ofBRCA1andBRCA2Mutations With Risk of Breast and Ovarian Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 1347.	7.4	390
193	Associations between breast density and a panel of single nucleotide polymorphisms linked to breast cancer risk: a cohort study with digital mammography. BMC Cancer, 2015, 15, 143.	2.6	15
194	The use of the Gail model, body mass index and SNPs to predict breast cancer among women with abnormal (BI-RADS 4) mammograms. Breast Cancer Research, 2015, 17, 1.	5.0	124
195	Breast MRI Fibroglandular Volume and Parenchymal Enhancement in BRCA1 and BRCA2 Mutation Carriers Before and Immediately After Risk-Reducing Salpingo-Oophorectomy. American Journal of Roentgenology, 2015, 204, 669-673.	2.2	34
196	Doseâ€“response effects of aerobic exercise on estrogen among women at high risk for breast cancer: a randomized controlled trial. Breast Cancer Research and Treatment, 2015, 154, 309-318.	2.5	34
197	RE: Breast Cancer Risk After Salpingo-Oophorectomy in Healthy BRCA1/2 Mutation Carriers: Revisiting the Evidence for Risk Reduction. Journal of the National Cancer Institute, 2015, 107, .	6.3	23
198	American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. Journal of Clinical Oncology, 2015, 33, 3660-3667.	1.6	603

#	Article	IF	Citations
199	Prevalence of mutations in a panel of breast cancer susceptibility genes in BRCA1/2-negative patients with early-onset breast cancer. Genetics in Medicine, 2015, 17, 630-638.	2.4	128
200	Development of a tiered and binned genetic counseling model for informed consent in the era of multiplex testing for cancer susceptibility. Genetics in Medicine, 2015, 17, 485-492.	2.4	79
201	Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 308-316.	2.5	22
202	Multiplex genetic testing: reconsidering utility and informed consent in the era of next-generation sequencing. Genetics in Medicine, 2015, 17, 97-98.	2.4	41
203	Characteristics of high risk breast cancer patients with mutations identified by multiplex panel testing.. Journal of Clinical Oncology, 2015, 33, 1511-1511.	1.6	1
204	A phase II open-label, multicenter study of single-agent rucaparib in the treatment of patients with relapsed ovarian cancer and a deleterious BRCA mutation.. Journal of Clinical Oncology, 2015, 33, 5513-5513.	1.6	12
205	Interest in and outcomes with return of individual genetic research results for inherited susceptibility to breast cancer.. Journal of Clinical Oncology, 2015, 33, e12503-e12503.	1.6	0
206	Information preferences of women with triple-negative breast cancer (TNBC).. Journal of Clinical Oncology, 2015, 33, e20585-e20585.	1.6	0
207	Meeting the educational needs of women with triple-negative breast cancer (TNBC).. Journal of Clinical Oncology, 2015, 33, e20580-e20580.	1.6	0
208	Uterine cancer (Ut Ca) following risk-reducing salpingo-oophorectomy (RRSO) in women with BRCA mutations (BRCA+): A multicenter, prospective study.. Journal of Clinical Oncology, 2015, 33, 1504-1504.	1.6	0
209	Impact of shortages of injectable oncology drugs on patient care. American Journal of Health-System Pharmacy, 2014, 71, 571-578.	1.0	40
210	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS Genetics, 2014, 10, e1004256.	3.5	47
211	Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2014, 148, 397-406.	2.5	56
212	Breast-Cancer Risk in Families With Mutations in PALB2. Obstetrical and Gynecological Survey, 2014, 69, 659-660.	0.4	1
213	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research, 2014, 16, 3416.	5.0	57
214	Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study. European Urology, 2014, 66, 489-499.	1.9	195
215	Modifiers of Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: A Systematic Review and Meta-Analysis. Journal of the National Cancer Institute, 2014, 106, dju091.	6.3	176
216	Panel testing for inherited susceptibility to breast, ovarian, and colorectal cancer. Genetics in Medicine, 2014, 16, 827-829.	2.4	12

#	Article	IF	Citations
217	Breast-Cancer Risk in Families with Mutations in PALB2. New England Journal of Medicine, 2014, 371, 497-506.	27.0	745
218	Long-term risk of medical conditions associated with breast cancer treatment. Breast Cancer Research and Treatment, 2014, 145, 233-243.	2.5	32
219	Contraceptive use and the role of contraceptive counseling in reproductive-aged women with cancer. Contraception, 2014, 90, 79-85.	1.5	42
220	Familial Breast Cancer Risk. Current Breast Cancer Reports, 2013, 5, 170-182.	1.0	8
221	A Classification Model for BRCA2 DNA Binding Domain Missense Variants Based on Homology-Directed Repair Activity. Cancer Research, 2013, 73, 265-275.	0.9	103
222	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	21.4	493
223	Incremental impact of breast cancer SNP panel on risk classification in a screening population of white and African American women. Breast Cancer Research and Treatment, 2013, 138, 889-898.	2.5	9
224	A genome-wide association study of breast cancer in women of African ancestry. Human Genetics, 2013, 132, 39-48.	3.8	70
225	Agreement of self-reported hormone receptor status with cancer registry data in young breast cancer patients. Cancer Epidemiology, 2013, 37, 601-605.	1.9	5
226	Fine mapping of breast cancer genome-wide association studies loci in women of African ancestry identifies novel susceptibility markers. Carcinogenesis, 2013, 34, 1520-1528.	2.8	26
227	Melanoma Genetic Testing, Counseling, and Adherence to Skin Cancer Prevention and Detection Behaviors. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 607-614.	2.5	34
228	Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk. PLoS Genetics, 2013, 9, e1003173.	3.5	105
229	Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. PLoS Genetics, 2013, 9, e1003212.	3.5	244
230	Biallelic Deleterious BRCA1 Mutations in a Woman with Early-Onset Ovarian Cancer. Cancer Discovery, 2013, 3, 399-405.	9.4	124
231	Are physician recommendations for BRCA1/2 testing in patients with breast cancer appropriate? A populationâ€based study. Cancer, 2013, 119, 3596-3603.	4.1	21
232	Risk of metachronous breast cancer after BRCA mutationâ€“associated ovarian cancer. Cancer, 2013, 119, 1344-1348.	4.1	58
233	A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1362-1370.	2.5	23
234	Genetic Susceptibility to Type 2 Diabetes and Breast Cancer Risk in Women of European and African Ancestry. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 552-556.	2.5	10

#	Article	IF	Citations
235	BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk. Journal of Medical Genetics, 2012, 49, 525-532.	3.2	97
236	Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 645-657.	2.5	47
237	Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 134-147.	2.5	513
238	How Genetic Variant Libraries Effectively Extend Gene Testing Patents: Implications for Intellectual Property and Good Clinical Care. Journal of Clinical Oncology, 2012, 30, 2943-2945.	1.6	4
239	Understanding Participation by African Americans in Cancer Genetics Research. Journal of the National Medical Association, 2012, 104, 324-330.	0.8	36
240	Breast and Ovarian Cancer Risk and Risk Reduction in Jewish BRCA1/2 Mutation Carriers. Journal of Clinical Oncology, 2012, 30, 1321-1328.	1.6	31
241	CD25 Blockade Depletes and Selectively Reprograms Regulatory T Cells in Concert with Immunotherapy in Cancer Patients. Science Translational Medicine, 2012, 4, 134ra62.	12.4	264
242	Low Rates of African American Participation in Genetic Counseling and Testing for BRCA1/2 Mutations: Racial Disparities or Just a Difference?. Journal of Genetic Counseling, 2012, 21, 676-683.	1.6	37
243	Characteristics of ductal carcinoma in situ found in BRCA1 and BRCA2 mutation carriers. Journal of the American College of Surgeons, 2012, 215, S126.	0.5	1
244	Follow-up Frequency and Compliance in Women with Probably Benign Findings on Breast Magnetic Resonance Imaging. Academic Radiology, 2012, 19, 406-411.	2.5	22
245	Cancer treatment according to BRCA1 and BRCA2 mutations. Nature Reviews Clinical Oncology, 2012, 9, 520-528.	27.6	69
246	Prophylactic Mastectomy and Risk-Reducing Salpingo-oophorectomy in BRCA1/2 Mutation Carriers. Current Breast Cancer Reports, 2012, 4, 199-206.	1.0	0
247	Breast Cancer Risk and 6q22.33: Combined Results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2. PLoS ONE, 2012, 7, e35706.	2.5	11
248	Evaluation of 19 susceptibility loci of breast cancer in women of African ancestry. Carcinogenesis, 2012, 33, 835-840.	2.8	64
249	Quality of Life in Long-Term Survivors of Metastatic Breast Cancer. Clinical Breast Cancer, 2012, 12, 119-126.	2.4	28
250	Ovarian cancer susceptibility alleles and risk of ovarian cancer inBRCA1andBRCA2mutation carriers. Human Mutation, 2012, 33, 690-702.	2.5	34
251	Lack of association between common single nucleotide polymorphisms in the TERT-CLPTM1L locus and breast cancer in women of African ancestry. Breast Cancer Research and Treatment, 2012, 132, 341-345.	2.5	12
252	Stumbling Blocks on the Path to Personalized Medicine in Breast Cancer: The Case of PARP Inhibitors for BRCA1/2-Associated Cancers. Cancer Discovery, 2011, 1, 29-34.	9.4	43

#	Article	IF	Citations
253	Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1-Interacting Genes. Cancer Research, 2011, 71, 5792-5805.	0.9	49
254	Therapeutic Approaches for Women Predisposed to Breast Cancer. Annual Review of Medicine, 2011, 62, 295-306.	12.2	33
255	The tubal hypothesis of ovarian cancer: caution needed. Lancet Oncology, The, 2011, 12, 1089-1091.	10.7	24
256	Breast Reconstruction â€“ A Historical Perspective on Available Techniques for Patients Electing Bilateral Mastectomy. Current Cancer Therapy Reviews, 2011, 7, 272-281.	0.3	0
257	Clinically Relevant Changes in Family History of Cancer Over Time. JAMA - Journal of the American Medical Association, 2011, 306, 172-8.	7.4	40
258	Breast Cancer Surgery Trend Changes Since the Introduction of BRCA1/2 Mutation Screening: A Retrospective Cohort Analysis of 158 Mutation Carriers Treated at a Single Institution. Annals of Surgical Oncology, 2011, 18, 745-751.	1.5	9
259	PALB2 mutations in familial breast and pancreatic cancer. Familial Cancer, 2011, 10, 225-231.	1.9	102
260	Clinical Management of Hereditary Breast Cancer Syndromes. Journal of Mammary Gland Biology and Neoplasia, 2011, 16, 17-25.	2.7	37
261	Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2011, 127, 287-296.	2.5	73
262	Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. Human Genetics, 2011, 130, 685-699.	3.8	18
263	Challenges to the Development of New Agents for Molecularly Defined Patient Subsets: Lessons From BRCA1/2-Associated Breast Cancer. Journal of Clinical Oncology, 2011, 29, 4224-4226.	1.6	23
264	Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Human Molecular Genetics, 2011, 20, 3304-3321.	2.9	68
265	Common Genetic Variation at BARD1 Is Not Associated with Breast Cancer Risk in BRCA1 or BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 1032-1038.	2.5	16
266	Genetic Variation in IGF2 and HTRA1 and Breast Cancer Risk among BRCA1 and BRCA2 Carriers. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 1690-1702.	2.5	17
267	Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers. Human Molecular Genetics, 2011, 20, 4732-4747.	2.9	32
268	Large Prospective Study of Ovarian Cancer Screening in High-Risk Women: CA125 Cut-Point Defined by Menopausal Status. Cancer Prevention Research, 2011, 4, 1401-1408.	1.5	53
269	Genetic Variation at 9p22.2 and Ovarian Cancer Risk for BRCA1 and BRCA2 Mutation Carriers. Journal of the National Cancer Institute, 2011, 103, 105-116.	6.3	40
270	Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma. Nature Medicine, 2011, 17, 941-943.	30.7	155

#	Article	IF	Citations
271	Long-Term Reactions to Genetic Testing forBRCA1andBRCA2Mutations: Does Time Heal Women's Concerns?. Journal of Clinical Oncology, 2011, 29, 4302-4306.	1.6	62
272	Interplay between BRCA1 and RHAMM Regulates Epithelial Apicobasal Polarization and May Influence Risk of Breast Cancer. PLoS Biology, 2011, 9, e1001199.	5.6	91
273	Homeostasis of peripheral FoxP3+ CD4+ regulatory T cells in patients with early and late stage breast cancer. Cancer Immunology, Immunotherapy, 2010, 59, 599-607.	4.2	35
274	Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers. Breast Cancer Research and Treatment, 2010, 124, 195-203.	2.5	58
275	Evaluation of established breast cancer risk factors as modifiers of BRCA1 or BRCA2: a multi-center case-only analysis. Breast Cancer Research and Treatment, 2010, 124, 441-451.	2.5	33
276	Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy. Breast Cancer Research and Treatment, 2010, 121, 389-398.	2.5	170
277	Predicting BRCA1 and BRCA2 gene mutation carriers: comparison of PENN II model to previous study. Familial Cancer, 2010, 9, 495-502.	1.9	45
278	Alcohol consumption and the risk of breast cancer among BRCA1 and BRCA2 mutation carriers. Breast, 2010, 19, 479-483.	2.2	24
279	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptorâ€“negative breast cancer in the general population. Nature Genetics, 2010, 42, 885-892.	21.4	309
280	Common Breast Cancer Susceptibility Alleles and the Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Implications for Risk Prediction. Cancer Research, 2010, 70, 9742-9754.	0.9	169
281	Common variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers. Human Molecular Genetics, 2010, 19, 2886-2897.	2.9	60
282	Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells. Clinical Cancer Research, 2010, 16, 3485-3494.	7.0	265
283	Association of Risk-Reducing Surgery in <emph type="ital">BRCA1</emph> or <emph type="ital">BRCA2</emph> Mutation Carriers With Cancer Risk and Mortality. JAMA - Journal of the American Medical Association, 2010, 304, 967.	7.4	1,241
284	Association of Risk-Reducing Surgery With Cancer Risks and Mortality in <emph type="ital">BRCA</emph> Mutation Carriersâ€”Reply. JAMA - Journal of the American Medical Association, 2010, 304, 2695.	7.4	1
285	Association of the VariantsCASP8D302H andCASP10V410I with Breast and Ovarian Cancer Risk inBRCA1andBRCA2Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2859-2868.	2.5	37
286	Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer. PLoS Genetics, 2010, 6, e1001183.	3.5	85
287	Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet, The, 2010, 376, 235-244.	13.7	1,584
288	Preventive surgery is associated with reduced cancer risk and mortality in women with BRCA1 and BRCA2 mutations. LDI Issue Brief, 2010, 16, 1-4.	1.1	14

#	Article	IF	Citations
289	Modification of Ovarian Cancer Risk by BRCA1/2-Interacting Genes in a Multicenter Cohort of BRCA1/2 Mutation Carriers. Cancer Research, 2009, 69, 5801-5810.	0.9	31
290	Multimodal Assessment of Protein Functional Deficiency Supports Pathogenicity of BRCA1 p.V1688del. Cancer Research, 2009, 69, 7030-7037.	0.9	16
291	Meta-analysis of Risk Reduction Estimates Associated With Risk-Reducing Salpingo-oophorectomy in BRCA1 or BRCA2 Mutation Carriers. Journal of the National Cancer Institute, 2009, 101, 80-87.	6.3	786
292	Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Human Molecular Genetics, 2009, 18, 4442-4456.	2.9	99
293	Collapse of the CD27+ B-Cell Compartment Associated with Systemic Plasmacytosis in Patients with Advanced Melanoma and Other Cancers. Clinical Cancer Research, 2009, 15, 4277-4287.	7.0	43
294	Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers. Gynecologic Oncology, 2009, 115, 135-137.	1.4	13
295	No evidence that CDKN1B (p27) polymorphisms modify breast cancer risk in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2009, 115, 307-313.	2.5	9
296	No evidence that GATA3 rs570613 SNP modifies breast cancer risk. Breast Cancer Research and Treatment, 2009, 117, 371-379.	2.5	12
297	Smoking and the risk of breast cancer in BRCA1 and BRCA2 carriers: an update. Breast Cancer Research and Treatment, 2009, 114, 127-135.	2.5	27
298	Clinical implications of low-penetrance breast cancer susceptibility alleles. Current Oncology Reports, 2009, 11, 8-14.	4.0	5
299	Refining BRCA1 and BRCA2 penetrance estimates in the clinic. Current Breast Cancer Reports, 2009, 1, 127-130.	1.0	2
300	Utilization of Religious Coping Strategies Among African American Women at Increased Risk for Hereditary Breast and Ovarian Cancer. Family and Community Health, 2009, 32, 218-227.	1.1	8
301	Breast cancer gene variants: separating the harmful from the harmless. Journal of Clinical Investigation, 2009, 119, 2895-2897.	8.2	8
302	The clinical management of BRCA1 and BRCA2 mutation carriers. Current Oncology Reports, 2008, 10, 47-53.	4.0	15
303	International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. International Journal of Cancer, 2008, 122, 2017-2022.	5.1	306
304	Common Breast Cancer-Predisposition Alleles Are Associated with Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. American Journal of Human Genetics, 2008, 82, 937-948.	6.2	257
305	The Relative Contribution of Point Mutations and Genomic Rearrangements in BRCA1 and BRCA2 in High-Risk Breast Cancer Families. Cancer Research, 2008, 68, 7006-7014.	0.9	100
306	Factors Determining Dissemination of Results and Uptake of Genetic Testing in Families with Known BRCA1/2 Mutations. Genetic Testing and Molecular Biomarkers, 2008, 12, 81-91.	1.7	130

#	Article	IF	Citations
307	Risk-Reducing Salpingo-Oophorectomy for the Prevention of BRCA1- and BRCA2-Associated Breast and Gynecologic Cancer: A Multicenter, Prospective Study. Journal of Clinical Oncology, 2008, 26, 1331-1337.	1.6	522
308	Cancer Yield of Mammography, MR, and US in High-Risk Women: Prospective Multi-Institution Breast Cancer Screening Study. Radiology, 2007, 244, 381-388.	7.3	361
309	Differential lysis of tumors by polyclonal T cell lines and T cell clones specific for hTERT. Cancer Biology and Therapy, 2007, 6, 1991-1996.	3.4	16
310	Telomerase-Specific T-Cell Immunity in Breast Cancer: Effect of Vaccination on Tumor Immunosurveillance. Cancer Research, 2007, 67, 10546-10555.	0.9	89
311	Breast Cancer Risk Among Male BRCA1 and BRCA2 Mutation Carriers. Journal of the National Cancer Institute, 2007, 99, 1811-1814.	6.3	316
312	Prophylactic oophorectomy in women at increased cancer risk. Current Opinion in Obstetrics and Gynecology, 2007, 19, 27-30.	2.0	54
313	RAD51 135Gâ†'C Modifies Breast Cancer Risk among BRCA2 Mutation Carriers: Results from a Combined Analysis of 19 Studies. American Journal of Human Genetics, 2007, 81, 1186-1200.	6.2	217
314	Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncology, The, 2007, 8, 26-34.	10.7	220
315	Large Genomic Rearrangement in BRCA1 and BRCA2 and Clinical Characteristics of Men with Breast Cancer in the United States. Clinical Breast Cancer, 2007, 7, 627-633.	2.4	7
316	Bilateral Prophylactic Oophorectomy and Bilateral Prophylactic Mastectomy in a Prospective Cohort of Unaffected BRCA1 and BRCA2 Mutation Carriers. Clinical Breast Cancer, 2007, 7, 875-882.	2.4	77
317	The Prevention of Hereditary Breast Cancer. Seminars in Oncology, 2007, 34, 401-405.	2.2	13
318	Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2007, 105, 221-228.	2.5	45
319	Cancer Risk Models: Translating Family History into Clinical Management. Annals of Internal Medicine, 2007, 147, 515.	3.9	5
320	Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncology, The, 2006, 7, 223-229.	10.7	333
321	Breast cancer screening behaviors among African American women with a strong family history of breast cancer. Preventive Medicine, 2006, 43, 385-388.	3.4	29
322	Low rates of acceptance of BRCA1 and BRCA2 test results among African American women at increased risk for hereditary breast-ovarian cancer. Genetics in Medicine, 2006, 8, 576-582.	2.4	68
323	Satisfaction with genetic counseling for BRCA1 and BRCA2 mutations among African American women. Patient Education and Counseling, 2006, 63, 196-204.	2.2	53
324	Childhood cancer in families with and without BRCA1 or BRCA2 mutations ascertained at a high-risk breast cancer clinic. Cancer Biology and Therapy, 2006, 5, 1098-1102.	3.4	28

#	Article	IF	Citations
325	Bilateral Risk-Reducing Oophorectomy in BRCA1 and BRCA2 Mutation Carriers. Journal of the National Comprehensive Cancer Network: JNCCN, 2006, 4, 177-182.	4.9	21
326	Telomerase vaccination has no detectable effect on SCID-repopulating and colony-forming activities in the bone marrow of cancer patients. Experimental Hematology, 2005, 33, 1275-1280.	0.4	46
327	Recruiting African American Women to Participate in Hereditary Breast Cancer Research. Journal of Clinical Oncology, 2005, 23, 7967-7973.	1.6	48
328	Knowledge, Attitudes, and Utilization ofBRCA1/2Testing among Women with Early-Onset Breast Cancer. Genetic Testing and Molecular Biomarkers, 2005, 9, 48-53.	1.7	46
329	Effect of Short-Term Hormone Replacement Therapy on Breast Cancer Risk Reduction After Bilateral Prophylactic Oophorectomy in BRCA1 and BRCA2 Mutation Carriers: The PROSE Study Group. Journal of Clinical Oncology, 2005, 23, 7804-7810.	1.6	396
330	Vaccination of Cancer Patients Against Telomerase Induces Functional Antitumor CD8+ T Lymphocytes. Clinical Cancer Research, 2004, 10, 828-839.	7.0	233
331	Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer, 2003, 97, 2972-2977.	4.1	672
332	Application of Breast Cancer Risk Prediction Models in Clinical Practice. Journal of Clinical Oncology, 2003, 21, 593-601.	1.6	174
333	Recent advances in breast cancer biology. Current Opinion in Oncology, 2002, 14, 589-593.	2.4	12
334	Lymphomas of the breast. Cancer, 2002, 94, 6-13.	4.1	197
335	Predictors of skeletal complications in patients with metastatic breast carcinoma. Cancer, 2000, 89, 363-368.	4.1	133